CACNA1S

Voltage-dependent L-type calcium channel subunit alpha-1S · Q13698 · CACNA1S on Sugi Atlas →

64,763 patent compounds predicted against CACNA1S, 42,296 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Clentiazem (SCHEMBL33909)	0.86	12/20
Clentiazem (SCHEMBL33910)	0.86	12/20
Diltiazem (SCHEMBL428935)	0.85	12/20
Clentiazem (SCHEMBL387182)	0.79	12/20
Clentiazem (SCHEMBL387183)	0.79	12/20
Diltiazem (SCHEMBL249454)	0.77	12/20
Diltiazem (SCHEMBL17776)	1.00	11/20
Diltiazem (SCHEMBL15457)	0.98	11/20
Diltiazem (SCHEMBL120772)	0.83	11/20
SCHEMBL116362	0.45	11/20
Nisoldipine (SCHEMBL39779)	1.00	9/20
Nisoldipine (SCHEMBL39780)	1.00	9/20
Nitrendipine (SCHEMBL38972)	0.91	9/20
(R)-Nitrendipine (SCHEMBL38973)	0.91	9/20
(S)-Nitrendipine (SCHEMBL120983)	0.91	9/20
Nimodipine (SCHEMBL34041)	0.82	8/20
(S)-Nimodipine (SCHEMBL34042)	0.82	8/20
Nimodipine (SCHEMBL142534)	0.81	8/20
SCHEMBL194784	0.51	8/20
Cilnidipine (SCHEMBL25550)	0.69	7/20

Clinical trials — most relevant to CACNA1S by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)	PHASE1	COMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS	nan	RECRUITING
International CRDS Registry	nan	RECRUITING
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia	nan	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Verapamil in Supraclavicular Brachial Plexus Block	nan	UNKNOWN
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism	nan	COMPLETED
A Natural History Study of RYR1-Related Disorders	nan	RECRUITING
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
High Density Mapping in Brugada Syndrome	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC.	nan	NOT_YET_RECRUITING
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNA1S binder may also engage these)

Protein	Name	Similarity
Q02789	—	1.000	Q02789 →
P07293	—	1.000	P07293 →
O57483	—	1.000	O57483 →
P22316	—	1.000	P22316 →
CACNA1D	Voltage-dependent L-type calcium channel subunit alpha-1D	1.000	landscape →
O73700	—	0.999	O73700 →
Q02485	—	0.998	Q02485 →
Q25452	—	0.994	Q25452 →
O35505	—	0.993	O35505 →
CACNA1C	Voltage-dependent L-type calcium channel subunit alpha-1C	0.992	landscape →
CACNA1F	Voltage-dependent L-type calcium channel subu	0.991	landscape →
C9D7C2	—	0.991	C9D7C2 →
P27732	—	0.989	P27732 →
Q99244	—	0.988	Q99244 →
P15381	—	0.987	P15381 →
P91645	—	0.987	P91645 →
Q01815	—	0.987	Q01815 →
P22002	—	0.986	P22002 →
O55017	—	0.986	O55017 →
Q6S5H8	—	0.986	Q6S5H8 →
P63141	—	0.985	P63141 →
P63142	—	0.985	P63142 →
P02719	—	0.985	P02719 →
P04775	—	0.985	P04775 →
P56698	—	0.985	P56698 →
Q6QIY3	—	0.985	Q6QIY3 →
Q99246	—	0.985	Q99246 →
Q2XVR6	—	0.984	Q2XVR6 →
Q6YLX9	—	0.984	Q6YLX9 →
Q9R053	—	0.984	Q9R053 →